128940.KS
128940.KS
KR7128940004
HanmiPharm
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±49.2% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.5x).

Beta (Market Relation)
0.53x
Defensive
Volatility (5Y p.a.)
49.2% p.a.
5-Year Horizon
Max Drawdown (5Y)
-50.2%
5-Year Horizon
Sharpe Ratio
0.24
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +35.5%
3 Years 55.9% -50.2% 0.23 +16.3%
5 Years 49.2% -50.2% 0.24 +14.4%
10 Years 46.7% -63.8% 0.01 +3.1%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Elevated Short-Term Volatility: 3Y volatility (55.9%) is noticeably higher than the 5Y average (49.2%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (49.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -63.8% in the extended horizon.
ende